Atossa Genetics intends to price public offering of its common stock

Bookrunner Aegis raises funds for working capital and clinical trials

By Devika Patel

Knoxville, Tenn., Aug. 30 – Atossa Genetics, Inc. said it will price a public sale of common stock.

Aegis Capital Corp. is the bookrunner.

Proceeds will be used for working capital and other general corporate purposes, including clinical trials.

Seattle-based Atossa Genetics has produced a device that detects and tests for precursors to breast cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.